Clopidogrel/aspirin - Chong Kun Dang

Drug Profile

Clopidogrel/aspirin - Chong Kun Dang

Alternative Names: Aspirin/clopidogrel - Chong Kun Dang; Coprigrel

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chong Kun Dang
  • Class Antiplatelets; Antipyretics; Pyridines; Salicylic acids; Small molecules; Thienopyridines
  • Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Coronary artery disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Coronary artery disease(In volunteers) in South Korea (PO)
  • 09 Mar 2013 Pharmacokinetics and adverse events data from a Phase-I trial in Coronary artery disease (in volunteers) presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2013)
  • 01 Sep 2011 Phase-I development is ongoing in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top